WHO ICTRP trial
Identification of OCT-based imaging biomarkers for predicting treatment response…
ChiCTR2500101034 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500101034 |
|---|---|
| Public title | Identification of OCT-based imaging biomarkers for predicting treatment response of refractory diabetic macular edema to faricimab and dexamethasone implant. A real-world prospective study |
| Scientific title | Identification of OCT-based imaging biomarkers for predicting treatment response of refractory diabetic macular edema to faricimab and dexamethasone implant. A real-world prospective study |
| Primary sponsor | Chinese University of Hong Kong |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Refractory diabetic macular edema |
| Interventions | Faricimab Group:After enrolment into the study, at least 3intravitreal faricimab injections will be performed every4 weeks, at baseline,4and8weeks.Onweek12 visit onwards,patients will be reviewed every 4 weeks, further injections will be… |
| Registration date | Apr 18, 2025 |
| Target size | Faricimab Group:40;Steroid treatment Group:40 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: